Recent progress in small molecule agents for the targeted therapy of triple-negative breast cancer

Islam, Rajibul; Lam, Kok Wai

doi:10.1016/j.ejmech.2020.112812

Cited by 32 publications

(29 citation statements)

References 164 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, a variety of drugs targeting the signal pathways are currently undergoing clinical trials. Some inhibitors have been used as potential medications for TNBC treatment, including PI3K, MEK, PARP, EGFR, VEGF, and AR inhibitors [22]. On the other hand, studies on operations and radiotherapy, especially for re-operations related to local-regional recurrence risk or distant metastasis, were rarely reported.…”

Section: Discussionmentioning

confidence: 99%

Quantitative and visualized analysis of 5,097 triple-negative breast cancer (TNBC) publications by using multiple machine learning algorithms: TNBC is an excellent forerunner in cancer research

Wang

Chen

Xue

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Triple-negative breast cancer (TNBC) is a subtype of breast cancer proposed at the beginning of this century, which is still the most challenging breast cancer subtype due to its aggressive behavior, including early relapse, metastatic spread, and poor survival. This study explores current research status and deficiencies from a macro perspective on TNBC publications by using machine learning methods. Methods: All publications under the MeSH term "Triple Negative Breast Neoplasms" in PubMed were searched and downloaded as of December 2020. R and Python were used to extract MeSH terms, geographic information and other abstracts from metadata. The Latent Dirichlet Allocation algorithm was applied to identify specific research topics. The Louvain algorithm was used to establish a topic network, identifying the relationship between the topics. Results: A total of 5,097 publications were identified, with an average annual growth rate of 33.5%. Only 88 countries and regions in the world participated in TNBC research. The publications contain about 25% of clinical trial-related research. The rapid clinical progress will provide an excellent example for diagnosing and treating other tumors, suggesting that TNBC is an excellent forerunner in cancer research. Publications of pathogenic mechanisms and drugs are most studied. Using the Topic model, we found that the publications were mainly focused on three aspects: treatment plan research, new biomarkers research, and the regulation mechanism for TNBC aggressive behavior. Conclusion: This study quantitively summarizes the current status of TNBC research from a macro perspective and will aid in redirecting basic and clinical research toward a better outcome of TNBC.

show abstract

Section: Discussionmentioning

confidence: 99%

Quantitative and visualized analysis of 5,097 triple-negative breast cancer (TNBC) publications by using multiple machine learning algorithms: TNBC is an excellent forerunner in cancer research

Wang

Chen

Xue

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

Section: Other Targeted Therapiesmentioning

confidence: 99%

“…Recent progress in preclinical studies with small-molecule agents for the targeted therapy of TNBC has been summarized in recent publications [28,110,155]. Islam et al described targeting the Bcl-2 family, proteasome, STAT3, histone deacetylase (HDACs), Src in TNBC in detail [155]. P53 mutations are prevalent in TNBC, which lead the cells to rely on checkpoint kinase 1 (ChK1) and ataxia telangiectasia related to Rad3 (ATR) for DNA repair management [110].…”

Section: Other Targeted Therapiesmentioning

confidence: 99%

Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions

Hossain

Majumder

David

et al. 2021

Cancers

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is an aggressive and heterogeneous subtype of breast cancer associated with a high recurrence and metastasis rate that affects African-American women disproportionately. The recent approval of targeted therapies for small subgroups of TNBC patients by the US ‘Food and Drug Administration’ is a promising development. The advancement of next-generation sequencing, particularly somatic exome panels, has raised hopes for more individualized treatment plans. However, the use of precision medicine for TNBC is a work in progress. This review will discuss the potential benefits and challenges of precision medicine for TNBC. A recent clinical trial designed to target TNBC patients based on their subtype-specific classification shows promise. Yet, tumor heterogeneity and sub-clonal evolution in primary and metastatic TNBC remain a challenge for oncologists to design adaptive precision medicine-based treatment plans.

show abstract

“…Small molecules have been recently reviewed for the treatment of TNBC including a handful of organometallic compounds. [13] In this review, we will highlight recent selected triple negative breast cancer clinical trials based on FDAapproved platinum compounds. We will also report on preclinical studies for other platinum-based metal-based compounds (until September of 2020) that are discrete molecules (we will not include metallic nanoparticles collected elsewhere).…”

Section: Introductionmentioning

confidence: 99%

Exploring the Potential of Metallodrugs as Chemotherapeutics for Triple Negative Breast Cancer

Nayeem

Contel

2021

Chemistry A European J

View full text Add to dashboard Cite

This review focuses on studies of coordination and organometallic compounds as potential chemotherapeutics against triple negative breast cancer (TNBC) which has one of the poorest prognoses and worst survival rates from all breast cancer types. At present, chemotherapy is still the standard of care for TNBC since only one type of targeted therapy has been recently developed. References for metal-based compounds studied in TNBC cell lines will be listed, and those of metal-specific reviews, but a detailed overview will also be provided on compounds studied in vivo (mostly in mice models) and those compounds for which some preliminary mechanistic data was obtained (in TNBC cell lines and tumors) and/or for which bioactive ligands have been used. The main goal of this review is to highlight the most promising metalbased compounds with potential as chemotherapeutic agents in TNBC.

show abstract

Recent progress in small molecule agents for the targeted therapy of triple-negative breast cancer

Cited by 32 publications

References 164 publications

Quantitative and visualized analysis of 5,097 triple-negative breast cancer (TNBC) publications by using multiple machine learning algorithms: TNBC is an excellent forerunner in cancer research

Quantitative and visualized analysis of 5,097 triple-negative breast cancer (TNBC) publications by using multiple machine learning algorithms: TNBC is an excellent forerunner in cancer research

Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions

Exploring the Potential of Metallodrugs as Chemotherapeutics for Triple Negative Breast Cancer

Contact Info

Product

Resources

About